100results about How to "Shorten bleeding time" patented technology

Devices, systems and methods for stimulating (e.g., noninvasively) a subject's inflammatory reflex are provided to reduce bleed time. The method may include the step of non-invasively stimulating the inflammatory reflex (e.g., the vagus nerve, the splenic nerve, the hepatic nerve, the facial nerve, and the trigeminal nerve) of a subject, such as by mechanical stimulation, in a manner which significantly reduces bleed time in the subject. Devices for non-invasively stimulating the inflammatory reflex may include a movable tip or actuator that is controlled to mechanically stimulate the ear. The devices may be hand-held or wearable, and may stimulate the cymba conchae region of the subject's ear.

Disclosed is a Chinese compound formulation for nourishing blood, regulating menstruation, stopping bleeding to prevent abortion and preparation method, which is prepared from prepared rehmannia root, Ligusticum wallichii, root of herbaceous peony, Chinese mugwort leafmulberry leaf, Chinese angelica root, licorice root and donkey-hide gelatin, and can be made into preparations with the forms of electuary, granule, tablet or capsule.

The invention relates to a drug for treating purpura. Raw materials to make effective components of the drug include radix astragali (prepared), sweet potato stem and leaf, ligustrum fruit, eclipta, elaginella (prepared), panax notoginseng, peanut sead-coat and liquorice. The raw materials can be made into various oral and external preparations through properly processing and/or acceptable auxiliary materials in pharmaceutics. With efficacies of Qi invigorating and Yin replenishing, and blood cooling and bleeding stopping, the invention is mainly used to treat purpura diseases caused by blood heat from Yin deficiency and Qi deficiency and blood absorbing failure, particularly mild and moderate thrombocytopenia.

The invention relates generally to the field of nucleic acids and more particularly to aptamers capable of binding to von Willebrand Factor useful as therapeutics in and diagnostics of thrombotic diseases and/or other diseases or disorders in which von Willebrand Factor mediated platelet aggregation has been implicated. The invention further relates to materials and methods for the administration of aptamers capable of binding to von Willebrand Factor.

The invention discloses a collagen aggregate based flocculent antibacterial hemostatic material and a preparation method thereof. The preparation method is characterized by comprising steps as follows: DCMC (dialdehyde carboxymethyl cellulose) and silver nitrate are blended, a mixed solution containing nano-silver is prepared through redox reaction, then certain amount of collagen aggregate and certain amount of polyvinylpyrrolidone are dissolved in the mixed solution sequentially, the mixture is subjected to processes including gradient dilution, dealcoholization, vacuum drying, impregnation, freeze-drying, moderate grinding, sterilization and the like, and the collagen aggregate based flocculent antibacterial hemostatic material is obtained finally. The material adopts the collagen aggregate more similar to a natural tissue collagen structure, and compared with common collagen materials, the prepared flocculent hemostatic material has excellent physical and chemical properties and biological properties such as structural stability, mechanical property, biological degradability, biocompatibility and the like, can promote wound healing and repair, has broad-spectrum antibacterial/antimicrobial activity of the nano-silver, has large contact surface with the wound surface, is high in hydrophilia and stickiness and can be used for hemostasis repair of body surface wound and general civil hemostasis emergency.

The invention provides a nanogel hemostatic material modified with modified glucan as well as preparation and an application of the nanogel hemostatic material. The nanogel hemostatic material is formed by polymerizing modified glucose and monomers containing vinyl, wherein the modified glucose is glucose modified with glycidyl methacrylate. The nanogel hemostatic material has excellent water absorption and good biocompatibility, the size is increased after the nanogel hemostatic material absorbs water to expand, a polymer hydrogel layer is formed and can block a wound to stop bleeding, modified glucan nonogel has an excellent hemostatic effect on traumatic hemorrhage such as venous hemorrhage, arterial hemorrhage, body surface hemorrhage as well as internal organ hemorrhage such as liver hemorrhage, is a good and novel hemostatic and has good application prospects in clinical trauma. The invention further provides a preparation method of the modified polysaccharide modified nanogel hemostatic material. The raw materials are cheap and easy to obtain, the reaction condition is mild, the reaction operation is simple, and post-treatment is convenient.

The invention relates to swelling medical biogel filler based on portulaca oleracea polysaccharide and flavone extract. The swelling medical biogel filler comprises a collagen gel component modified by compound polysaccharide, a swelling compound polysaccharide gel component and a nano hydroxy phosphorite component loaded with portulaca oleracea flavone extract and calcium ion. The swelling medical biogel filler is a framework supporting polysaccharide filling material integrating effects of absorbing seepage, stopping bleeding, filling and promoting healing and has antibacterial and antipyrotic characteristics. Portulaca oleracea is rich in source, and polysaccharide is low in preparation cost, so that the swelling medical biogel filler is suitable for industrial production.

The invention belongs to the technical field of chitosan derivative preparation, and particularly provides a functionalized chitosan microsphere and a preparation method and application thereof. The method comprises the steps that high-molecular-weight chitosan is degraded to obtain a low-molecular-weight chitosan solution, then chitosan is subjected to functional modification through lactobionic acid and ammonium ferrous sulfate, and finally, under the action of sodium polyphosphate, cross-linking reaction is conducted to obtain the functional chitosan microsphere. The functional chitosan microsphere can be used for preparing hemostatic materials, the bleeding time is greatly shortened, the bleeding amount is reduced, and the hemostatic effect is good.

The invention provides antibacterial medical hemostasis absorbent cotton gauze, which consists of medicine dressing and a tissue material carrying the medicine dressing, wherein the medicine dressingis prepared from traditional Chinese medicine and western medicine; the tissue material carrying the medicine dressing is blended by scleroprotein fiber and cotton fiber. The hemostasis and the antibacterial effects are integrated; the obvious effects are achieved on abnormal bleeding in operations of lung, liver, pancreas, adrenal gland and the like, the bleeding except for obstetrics departmentand postpartum hemorrhage, urinary tract bleeding and the like; in addition, the antibacterial medical hemostasis absorbent cotton gauze can be used under the conditions of great and deep wound and great bleeding quantity; the hemostasis is fast; the wound surface wound recovery is facilitated; meanwhile, the antibacterial spectrum is wide; the sterilization power is strong; the action is fast; the effectiveness can also be achieved on pseudomonas aeruginosa, klebsiella, escherichia coli, enterobacter, staphylococcus, mycoplasma and chlamydia; in addition, good effects are achieved on trimethoprim drug resistant bacteria, penicillin drug resistant staphylococcus aureus andtylosin or tiamulin drug resistant mycoplasma.

The invention relates to the use of adeno-associated virus (AAV) vectors to achieve long term expression of a transgene in the liver of a juvenile subject. The invention includes the stable long-term amelioration of disease symptoms of the subjection following a single administration of an AAV vector to a juvenile subject, wherein the AAV vector delivers the transgene to the subject's liver.

The invention discloses an oligopeptide containing an Hyp-Gly sequence and having antiplatelet and antithrombotic functions. The invention provides the oligopeptide containing the Hyp-Gly sequence orsalt forms thereof. The oligopeptide containing an OG sequence can be prepared through artificial synthesis as well as enzymolysis of fish skin. The molecular weight of the oligopeptide containing theOG sequence is smaller than 1,000 Da, the mass ratio of the oligopeptide to total enzyme-digested products is 65%-95%, and the oligopeptide has a specific inhibition effect on ADP-induced platelet aggregation, can inhibit thrombosis, does not affect the blood coagulation function, does not prolong the bleeding time and is very small in bleeding risk; and the oligopeptide has the characteristics of resistance to gastrointestinal tract digestive enzyme enzymolysis and easiness in absorption.

The invention provides for dry spray compositions comprising co-polymers comprising a core, water-soluble polymer and a peptide.

Disclosed are methods for treating bleeding disorders, such as hemophilia, in subjects in need thereof by administering an antibody that specifically binds CD73. The methods reduce production of adenosine, increase platelet activation and/or enhance the level of coagulation on the platelet surface to reduce and/or stop bleeding. In some embodiments, the methods can further include co-administering Factor VIII to treat the bleeding disorder.

The invention relates to a pharmaceutical composition for treating hemorrhoid and process for preparation, wherein the composition comprises pagodatree fruit 385.5g, red peony root 193g, bark of peony root 193g, ledebouriella root 193g, Chinese angelica root 193g, bitter orange 193g, baikal skullcap root 193g and processed radix aconiti 8g.